FOFWEEKLY·2025-12-10 10:00Core Viewpoint - The establishment of the Anhui Gaotou Guotai Haitong Health M&A Fund marks a significant step in the investment phase, focusing on innovative drug sectors such as oncology and autoimmune diseases [1] Group 1: Fund Overview - The Anhui Gaotou Guotai Haitong Health M&A Fund has a total scale of 500 million yuan [1] - The fund is managed by Guotai Junan Innovation Investment Co., Ltd., a subsidiary of Guotai Haitong [1] - The fund is established in collaboration with leading biopharmaceutical companies and diversified capital sources [1] Group 2: Investment Focus - The fund primarily targets innovative drug fields, including anti-tumor drugs, autoimmune disease drugs, and endocrine and metabolic disease drugs [1] - The investment strategy aims to capitalize on growth opportunities arising from the development of the biopharmaceutical industry [1]